Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601293 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL10070056 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL19818246 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL13312942 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL680648 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL7752845 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3047337 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL16202652 | 1.00 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL4843434 | 0.97 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3914000 | 0.97 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8067440-B2 | Phosphonium salts derivatives and uses thereof | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20110092683-A1 | PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2011-04-21 | — | — | US | disclosed |
| US-7880037-B2 | Phosphonium supported triphenylphosphine; for controlling solubility of a molecule; oxidation of Cinnamyl Alcohol using above catalyst system | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2011-02-01 | — | — | US | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-7695801-B2 | Optical systems and refractive index-matching compositions | AVAGO TECHNOLOGIES FIBER IP (SINGAPORE) PTE. LTD. (SG) | 2010-04-13 | — | — | US | disclosed |
| US-20070197477-A1 | PHOSPHONIUM SALTS DERIVATIVES | VALORISATION-RECHERECHE (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20050170146-A1 | Optical systems and refractive index-matching compositions | AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD. (SG) | 2005-08-04 | — | — | US | disclosed |
| US-6890619-B2 | Optical systems and refractive index-matching compositions | AGILENT TECHNOLOGIES, INC. (US) | 2005-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | TRPA1 3391/4885TRPM8 4099/4885CA1 3760/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TRPA1 35/4885TRPM8 111/4885CA1 2651/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TRPA1 4793/4885TRPM8 4443/4885CA1 4879/4885 |
| US-20070197477-A1 | PHOSPHONIUM SALTS DERIVATIVES | PI4K2A, PIP4K2A, PI4K2B | TRPA1 3246/4885TRPM8 4257/4885CA1 589/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TRPA1 3551/4885TRPM8 4476/4885CA1 4622/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TRPA1 3551/4885TRPM8 4476/4885CA1 4622/4885 |
| US-20110092683-A1 | PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF | PI4K2A, PIP4K2A, PI4K2B | TRPA1 3414/4885TRPM8 4190/4885CA1 568/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TRPA1 3551/4885TRPM8 4476/4885CA1 4622/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TRPA1 3551/4885TRPM8 4476/4885CA1 4622/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TRPA1 3551/4885TRPM8 4476/4885CA1 4622/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TRPA1 4793/4885TRPM8 4443/4885CA1 4879/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TRPA1 4793/4885TRPM8 4443/4885CA1 4879/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TRPA1 4793/4885TRPM8 4443/4885CA1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.